Literature DB >> 15036558

Endogenous neuroprotection in the retina.

Steven Roth1.   

Abstract

Ischemic preconditioning (IPC) protects the rat retina against the injury that ordinarily follows severe ischemia. The retina is protected against the damage following severe ischemia for up to 72h after the application of IPC. However, there is no early preconditioning, i.e. protective effects starting within hours of preconditioning. The IPC stimulus consists of a brief, non-damaging period of ischemia. It results in complete preservation of retinal structure and function following ischemia, and is thus the most robust neuroprotection demonstrated in the retina to date. Release of adenosine, de novo protein synthesis, and mediators such as protein kinase C and K(+) ATP channels are required for IPC protection. Both the adenosine A1 and A2a receptors are involved. However, the molecular mechanisms for neuroprotection have not been completely described. It appears that both increased expression of protective proteins and decreased expression of pro-apoptotic proteins are involved. In addition, IPC prevents hypoperfusion following severe ischemia. Further study of the IPC phenomenon could lead to an enhanced understanding of the mechanisms of ischemic damage and its prevention in the retina.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036558     DOI: 10.1016/j.brainresbull.2003.07.006

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  20 in total

1.  Induction of ischemic tolerance protects the retina from diabetic retinopathy.

Authors:  Diego C Fernandez; Pablo H Sande; Mónica S Chianelli; Hernán J Aldana Marcos; Ruth E Rosenstein
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders.

Authors:  Muayyad R Al-Ubaidi; Muna I Naash; Shannon M Conley
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

3.  Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Authors:  Jeffrey M Gidday
Journal:  Cond Med       Date:  2018-02-15

4.  Ionic dysregulatory phenotyping of pathologic retinal thinning with manganese-enhanced MRI.

Authors:  Bruce A Berkowitz; Marius Gradianu; Stephen Schafer; Ying Jin; Andre Porchia; Raymond Iezzi; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-24       Impact factor: 4.799

5.  High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma.

Authors:  Michael G Anderson; Richard T Libby; Douglas B Gould; Richard S Smith; Simon W M John
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

6.  Transfer of lens-specific transcripts to retinal RNA samples may underlie observed changes in crystallin-gene transcript levels after ischemia.

Authors:  Willem Kamphuis; Frederike Dijk; Willem Kraan; Arthur A B Bergen
Journal:  Mol Vis       Date:  2007-02-08       Impact factor: 2.367

Review 7.  Novel neuroprotective strategies in ischemic retinal lesions.

Authors:  Krisztina Szabadfi; Laszlo Mester; Dora Reglodi; Peter Kiss; Norbert Babai; Boglarka Racz; Krisztina Kovacs; Aliz Szabo; Andrea Tamas; Robert Gabriel; Tamas Atlasz
Journal:  Int J Mol Sci       Date:  2010-02-03       Impact factor: 6.208

8.  Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.

Authors:  Yanli Zhu; Lihong Zhang; Jeffrey M Gidday
Journal:  J Ocul Pharmacol Ther       Date:  2008-12       Impact factor: 2.671

9.  Endogenous leukemia inhibitory factor protects photoreceptor cells against light-induced degeneration.

Authors:  Sandra Bürgi; Marijana Samardzija; Christian Grimm
Journal:  Mol Vis       Date:  2009-08-18       Impact factor: 2.367

10.  Global gene expression profiling of ischemic preconditioning in the rat retina.

Authors:  W Kamphuis; F Dijk; S van Soest; A A B Bergen
Journal:  Mol Vis       Date:  2007-06-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.